Adherex Technologies (FENC)
(Delayed Data from NSDQ)
$6.61 USD
+0.04 (0.61%)
Updated Jul 25, 2024 04:00 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Adherex Technologies Inc. [FENC]
Reports for Purchase
Showing records 81 - 100 ( 106 total )
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
Termination of Coverage - Analyst(s) Departure
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
Term Loan Facility Obtained; PEDMARK Filing Completion Approaches; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
PEDMARK U.S. Market Entry Expected in Summer 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
FENC Initiates Rolling NDA with Broad Label for PEDMARK
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
PEDMARK Regulatory Submission Nears Completion; 3Q18 Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and $17 YE:19 price target
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WERTHER C
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
Patient Meeting Points to Broad Label Support, Will FDA Follow?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
2Q18 Financial Results Reported; Approaching PEDMARK- Regulatory Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
2Q Update, Positive Momentum Going into Likely PEDMARK Approval Next Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
PIP Acceptance sets up Favorable Near-Term Setup for Shares
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
Fennec Slated to Join Russell 3000 Stock Index; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
1Q 2018 Financial Results Reported; Looking Ahead to PEDMARK - NDA Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
Near-term Commercial Potential Remains Undervalued
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
PEDMARK Receives Breakthrough Therapy Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Adherex Technologies Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.